NKGen Biotech IncNASDAQ:NKGNNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.5200
- TODAY'S CHANGE (%)-0.1200 (-7.3171%)
- Bid / Lots1.5100/ 4
- Ask / Lots1.5200/ 2
- Open / Previous Close1.5900 / 1.6400
- Day Range
- 52 Week Range
- Volume374,275
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NKGN |
|---|---|---|
| 09:32 ET | 26911 | 1.635 |
| 09:34 ET | 1094 | 1.6041 |
| 09:36 ET | 800 | 1.64 |
| 09:38 ET | 2269 | 1.63 |
| 09:39 ET | 750 | 1.615 |
| 09:41 ET | 2916 | 1.625 |
| 09:43 ET | 5838 | 1.574 |
| 09:45 ET | 13071 | 1.5897 |
| 09:48 ET | 421 | 1.57 |
| 09:50 ET | 33473 | 1.53 |
| 09:52 ET | 14731 | 1.5197 |
| 09:54 ET | 31617 | 1.4803 |
| 09:56 ET | 15345 | 1.5198 |
| 09:57 ET | 8818 | 1.5206 |
| 09:59 ET | 7637 | 1.549 |
| 10:01 ET | 2026 | 1.584 |
| 10:03 ET | 400 | 1.585 |
| 10:06 ET | 425 | 1.58 |
| 10:08 ET | 1182 | 1.57 |
| 10:10 ET | 600 | 1.56 |
| 10:12 ET | 667 | 1.56 |
| 10:14 ET | 100 | 1.568 |
| 10:15 ET | 1000 | 1.555 |
| 10:21 ET | 504 | 1.5504 |
| 10:24 ET | 4053 | 1.555 |
| 10:26 ET | 5112 | 1.59 |
| 10:30 ET | 700 | 1.571 |
| 10:32 ET | 10184 | 1.56 |
| 10:33 ET | 5822 | 1.56 |
| 10:35 ET | 1494 | 1.5382 |
| 10:37 ET | 1540 | 1.5445 |
| 10:44 ET | 1911 | 1.57 |
| 10:50 ET | 2186 | 1.5 |
| 10:53 ET | 5000 | 1.52 |
| 10:55 ET | 1152 | 1.51 |
| 10:57 ET | 700 | 1.501 |
| 11:00 ET | 200 | 1.5035 |
| 11:02 ET | 531 | 1.51 |
| 11:04 ET | 1620 | 1.513 |
| 11:06 ET | 3735 | 1.51 |
| 11:08 ET | 251 | 1.5099 |
| 11:09 ET | 2905 | 1.5057 |
| 11:11 ET | 140 | 1.5085 |
| 11:13 ET | 200 | 1.51 |
| 11:15 ET | 200 | 1.5094 |
| 11:18 ET | 531 | 1.5 |
| 11:20 ET | 100 | 1.51 |
| 11:22 ET | 888 | 1.5001 |
| 11:24 ET | 200 | 1.5 |
| 11:26 ET | 3037 | 1.5 |
| 11:29 ET | 100 | 1.5094 |
| 11:31 ET | 200 | 1.51 |
| 11:33 ET | 251 | 1.5 |
| 11:36 ET | 894 | 1.51 |
| 11:47 ET | 100 | 1.51 |
| 11:49 ET | 7085 | 1.495 |
| 11:51 ET | 100 | 1.5 |
| 11:54 ET | 100 | 1.505 |
| 11:56 ET | 100 | 1.5 |
| 12:00 ET | 1000 | 1.5 |
| 12:03 ET | 500 | 1.49 |
| 12:07 ET | 100 | 1.49 |
| 12:09 ET | 6815 | 1.48 |
| 12:12 ET | 800 | 1.4797 |
| 12:14 ET | 1000 | 1.48 |
| 12:16 ET | 1688 | 1.48 |
| 12:18 ET | 1000 | 1.48 |
| 12:21 ET | 470 | 1.4797 |
| 12:23 ET | 642 | 1.48 |
| 12:27 ET | 1000 | 1.5 |
| 12:34 ET | 1349 | 1.4804 |
| 12:36 ET | 707 | 1.4809 |
| 12:38 ET | 2000 | 1.4999 |
| 12:41 ET | 9388 | 1.5156 |
| 12:43 ET | 3408 | 1.52 |
| 12:45 ET | 500 | 1.52 |
Yesterday
DJ NKGen Biotech Shares Rise 15% After FDA Clears Application for Parkinson's Disease Therapy, from 8:53AM ET on Monday Apr 29, 2024 by Dow Jones
8:53AM ET on Monday Apr 29, 2024 by Dow JonesNKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson's Disease, from 8:00AM ET on Monday Apr 29, 2024 by Dow Jones
8:00AM ET on Monday Apr 29, 2024 by Dow Jones
Apr 25, 2024
Apr 24, 2024
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, from 4:45PM ET on Wednesday Apr 24, 2024 by Dow Jones
4:45PM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 18, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NKGen Biotech Inc | 37.4M | -0.3x | --- |
NRX Pharmaceuticals Inc | 37.2M | -0.9x | --- |
Brainstorm Cell Therapeutics Inc | 36.9M | -1.3x | --- |
ProMIS Neurosciences Inc | 37.9M | -1.6x | --- |
Xilio Therapeutics Inc | 38.4M | -0.4x | --- |
Carmell Corp | 38.5M | -1.4x | --- |
Company Information
NKGen Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing its (SuperNK) SNK (super-activated) platform. SNK involves the infusion of one’s own activated NK cells into the body to improve immune system function, eliminate diseased or abnormal cells and prevent recurrence. SNK uses pure NK cells harvested from the patient’s blood, activated and infused back into the patient’s body. SNK has a therapeutic potential within the areas of cancer, autoimmune and neurodegenerative diseases. Autologous NK cell immunotherapy is a treatment that provides immune enhancement using pure NK cells harvested from a patient’s body. It is also focused on conducting clinical trials with its super-activated NK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).
Contact Information
- Headquarters
- 3001 Daimler St,SANTA ANA, CA, United States 92705
- Phone
- 949-396-6830
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- Sangwoo Park
- President, Chief Executive Officer, Director
- Paul Song
- Interim Chief Financial Officer
- James Graf
- Chief Operating Officer
- Pierre Gagnon
- Executive Vice President, General Counsel, Secretary, Director
- Anthony Kuznik
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $37.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 22.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-5.24 |
Book Value | $-2.68 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
